Astera Labs Quarterly Income Statements Chart
Quarterly
|
Annual
Astera Labs Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|
| revenue | 191,925,000 | 159,442,000 | 141,096,000 | 113,086,000 | 76,850,000 | 65,258,000 |
| yoy | 149.74% | 144.33% | ||||
| qoq | 20.37% | 13.00% | 24.77% | 47.15% | 17.76% | |
| cost of revenue | 46,362,000 | 40,031,000 | 36,648,000 | 25,209,000 | 16,996,000 | 14,738,000 |
| gross profit | 145,563,000 | 119,411,000 | 104,448,000 | 87,877,000 | 59,854,000 | 50,520,000 |
| yoy | 143.20% | 136.36% | ||||
| qoq | 21.90% | 14.33% | 18.86% | 46.82% | 18.48% | |
| gross margin % | 75.84% | 74.89% | 74.03% | 77.71% | 77.88% | 77.42% |
| operating expenses | ||||||
| research and development | 66,724,000 | 64,554,000 | 56,524,000 | 50,659,000 | 40,089,000 | 53,558,000 |
| sales and marketing | 18,609,000 | 21,702,000 | 22,818,000 | 23,248,000 | 22,076,000 | 55,510,000 |
| general and administrative | 20,456,000 | 21,870,000 | 24,962,000 | 22,866,000 | 22,036,000 | 24,419,000 |
| total operating expenses | 105,789,000 | 108,126,000 | 104,304,000 | 96,773,000 | 84,201,000 | 133,487,000 |
| operating income | 39,774,000 | 11,285,000 | 144,000 | -8,896,000 | -24,347,000 | -82,967,000 |
| yoy | -263.36% | -113.60% | ||||
| qoq | 252.45% | 7736.81% | -101.62% | -63.46% | -70.65% | |
| operating margin % | 20.72% | 7.08% | 0.10% | -7.87% | -31.68% | -127.14% |
| interest income | 10,885,000 | 10,432,000 | 10,558,000 | 10,912,000 | 10,264,000 | 2,554,000 |
| income before income taxes | 50,659,000 | 21,717,000 | 10,702,000 | 2,016,000 | -14,083,000 | -80,413,000 |
| income tax benefit | -560,000 | -10,102,000 | -6,537,000 | |||
| net income | 51,219,000 | 31,819,000 | 24,713,000 | -7,593,000 | -7,546,000 | -92,995,000 |
| yoy | -778.76% | -134.22% | ||||
| qoq | 60.97% | 28.75% | -425.47% | 0.62% | -91.89% | |
| net income margin % | 26.69% | 19.96% | 17.52% | -6.71% | -9.82% | -142.50% |
| net income per share | ||||||
| basic | 0.31 | 0.19 | ||||
| diluted | 0.29 | 0.18 | ||||
| weighted-average shares used for eps calculation | ||||||
| basic | 165,428 | 163,194 | ||||
| diluted | 178,100 | 178,116 | ||||
| other comprehensive income | ||||||
| unrealized gain on marketable securities, net of taxes | 846 | 1,602 | -4,004 | 4,782 | ||
| total other comprehensive gain | 846 | 1,602 | 1,042.75 | 4,782 | ||
| total comprehensive income | 52,065 | 33,421 | ||||
| income tax provision | -14,011,000 | 9,609,000 | 12,582,000 | |||
| net income per share | ||||||
| basic and diluted | 0.25 | -0.05 | -0.05 | -1.77 | ||
| weighted-average shares used for eps calculation | ||||||
| basic and diluted | 131,262 | 156,831 | 155,199 | 52,532 | ||
| other comprehensive loss | ||||||
| total comprehensive loss | 20,709 | -2,811 | -7,839,000 | -93,313,000 | ||
| unrealized losses on marketable securities, net of taxes | -293,000 | |||||
| total other comprehensive loss | -293,000 | |||||
| unrealized gains on marketable securities, net of taxes | -318,000 | |||||
| total other comprehensive income | -318,000 |
We provide you with 20 years income statements for Astera Labs stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Astera Labs stock. Explore the full financial landscape of Astera Labs stock with our expertly curated income statements.
The information provided in this report about Astera Labs stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.